Category - Developments

Developments

Meta-analysis of 17 studies shows no clinically meaningful benefit from anti-amyloid Alzheimer’s drugs

According to the authors of a new Cochrane systemic review which examined data from 17 clinical trials with a total of 20,342 participants, the effect of amyloid‐beta‐targeting monoclonal antibodies on cognitive...

April 16, 2026

Developments

FDA grants Arbutus fast track designation for imdusiran in cHBV

Arbutus Biopharma (NASDAQ: ABUS) has announced that the FDA has granted fast track designation for imdusiran for the treatment of chronic hepatitis B (cHBV). Imdusiran is an RNAi therapeutic specifically designed to...

April 15, 2026

Developments

Stereotaxis to acquire Robocath

Stereotaxis (NYSE: STXS) has announced that it has entered into a definitive agreement to acquire closely held Robocath, a venture-backed innovator of robotic techniques for interventional cardiology and...

April 15, 2026

Developments

MHRA clears Poolbeg for cancer immunotherapy trial

Poolbeg Pharma (AIM: POLB; OTC: POLBF; FRA: POLBF) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the company clinical trial authorization for its TOPICAL trial with...

April 15, 2026

Developments

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk...

April 14, 2026

Developments

Nature Medicine publishes Actuate’s data from trial of elraglusib + chemo in mPC

Actuate Therapeutics (NASDAQ: ACTU) has announced the publication of new data in Nature Medicine from its Phase 2 clinical trial evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP)...

April 14, 2026

Developments

Cellectar enrolls first patient in Phase 1b study of CLR 125 targeting TNBC

Cellectar Biosciences (NASDAQ: CLRB) has announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 (CLR 125) for the potential treatment of triple negative breast cancer (TNBC). According to...

April 14, 2026

Developments

Firefly builds world’s first 200,000+ EEG/ERP brain scan depository

Firefly Neuroscience (NASDAQ: AIFF) has achieved a major operational and commercial milestone with more than 200,000 EEG/ERP (human brain function) scans. Through its acquisition of Evoke Neuroscience in May 2025...

April 13, 2026

Developments

MetaVia doses first patient in study of DA-1726 in obesity

MetaVia (NASDAQ: MTVA) has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. According to MetaVia, Part 3...

April 10, 2026

Developments

Annovis’ $10 million financing secures path to NDA for buntanetap in AD

Annovis Bio (NYSE: ANVS) has announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds extending its cash runway through Phase 3 Alzheimer’s disease (AD) six-month NDA...

April 10, 2026

Category - Developments

Subscribe